The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study
- PMID: 16814646
- DOI: 10.1016/j.jacc.2006.02.052
The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study
Abstract
Objectives: This study was designed to determine the relationship between clopidogrel and early ST-segment resolution (STRes) and the interaction of the two with clinical outcomes after fibrinolysis.
Background: ST-segment resolution is an early noninvasive marker of coronary reperfusion.
Methods: The CLARITY-TIMI 28 (Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction 28) trial randomized 3,491 patients with ST-segment elevation myocardial infarction (STEMI) undergoing fibrinolysis to clopidogrel versus placebo. ST-segment resolution was defined as complete (>70%), partial (30% to 70%), or none (<30%).
Results: Electrocardiograms were valid for interpretation in 2,431 patients at 90 min and 2,087 at 180 min. There was no difference in the rate of complete STRes between the clopidogrel and placebo groups at 90 min (38.4% vs. 36.6% at 90 min). When patients were stratified by STRes category, treatment with clopidogrel resulted in greater benefit among those with evidence of early STRes, with greater odds of an open artery at late angiography in patients with partial (odds ratio [OR] 1.4, p = 0.04) or complete (OR 2.0, p < 0.001) STRes, but no improvement in those with no STRes at 90 min (OR 0.89, p = 0.48) (p for interaction = 0.003). Clopidogrel was also associated with a significant reduction in the odds of an in-hospital death or myocardial infarction in patients who achieved partial (OR 0.30, p = 0.003) or complete STRes at 90 min (OR 0.49, p = 0.056), whereas clinical benefit was not apparent in patients who had no STRes (OR 0.98, p = 0.95) (p for interaction = 0.027). By 30 days, the clinical benefit of clopidogrel was predominately seen in patients with complete STRes.
Conclusions: Clopidogrel appears to improve late coronary patency and clinical outcomes by preventing reocclusion of open arteries rather than by facilitating early reperfusion.
Similar articles
-
Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction.Am Heart J. 2010 Jan;159(1):55-62. doi: 10.1016/j.ahj.2009.10.033. Am Heart J. 2010. PMID: 20102867 Clinical Trial.
-
A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study.Eur Heart J. 2007 Sep;28(17):2070-6. doi: 10.1093/eurheartj/ehm210. Epub 2007 Jun 28. Eur Heart J. 2007. PMID: 17600039 Clinical Trial.
-
Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study.Am Heart J. 2008 Jan;155(1):133-9. doi: 10.1016/j.ahj.2007.08.034. Epub 2007 Nov 19. Am Heart J. 2008. PMID: 18082504 Clinical Trial.
-
Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Clin Ther. 2008. PMID: 19281914 Review.
-
Clinical use of clopidogrel in acute coronary syndrome.Int J Clin Pract. 2007 Mar;61(3):473-81. doi: 10.1111/j.1742-1241.2007.01315.x. Int J Clin Pract. 2007. PMID: 17313616 Review.
Cited by
-
Serum NT-proBNP on admission can predict ST-segment resolution in patients with acute myocardial infarction after primary percutaneous coronary intervention.Herz. 2015 Sep;40(6):898-905. doi: 10.1007/s00059-015-4309-0. Epub 2015 May 22. Herz. 2015. PMID: 25997425 Clinical Trial.
-
Significance of antiplatelet therapy in emergency myocardial infarction treatment.Postepy Kardiol Interwencyjnej. 2014;10(1):32-9. doi: 10.5114/pwki.2014.41466. Epub 2014 Mar 23. Postepy Kardiol Interwencyjnej. 2014. PMID: 24799926 Free PMC article. Review.
-
Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial.Clin Cardiol. 2014 Mar;37(3):160-6. doi: 10.1002/clc.22235. Epub 2014 Jan 22. Clin Cardiol. 2014. PMID: 24452727 Free PMC article. Clinical Trial.
-
Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism.Circ Res. 2013 Jan 4;112(1):174-94. doi: 10.1161/CIRCRESAHA.111.300271. Circ Res. 2013. PMID: 23287454 Free PMC article.
-
Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus.J Thromb Thrombolysis. 2012 Jul;34(1):20-30. doi: 10.1007/s11239-012-0744-4. J Thromb Thrombolysis. 2012. PMID: 22562147 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
